Trademark Overview
On Wednesday, January 19, 2022, a trademark application was filed for ATN with the United States Patent and Trademark Office. The USPTO has given the ATN trademark a serial number of 97227543. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, February 14, 2023. This trademark is owned by NeuExcell Therapeutics Inc.. The ATN trademark is filed in the Pharmaceutical Products category with the following description:
Research and development of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, epilepsy, physical injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, infection, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, cerebral venous sinus thrombosis, retinal disease and other disease arising from neuronal damage; and testing, inspection, research or development of pharmaceutical preparations for gene therapy or small molecule treatment
